Corpus overview


Overview

MeSH Disease

Human Phenotype

Pneumonia (1295)

Fever (190)

Cough (154)

Respiratory distress (95)

Hypertension (79)


Transmission

Seroprevalence
    displaying 1051 - 1060 records in total 1295
    records per page




    Different clinical presentations of two renal transplant recipients with Coronavirus Disease MESHD 2019: a case report

    Authors: Jing Li; Gang Chen; chao chen

    doi:10.21203/rs.3.rs-19537/v1 Date: 2020-03-26 Source: ResearchSquare

    Background: The Coronavirus Disease MESHD 2019 (COVID-19) caused by severe acute respiratory syndrome Coronavirus-2 MESHD has spread rapidly worldwide and disease spread is currently increasing. The clinical picture of transplant recipients and the effect of the anti-rejection immunosuppressive regimens on the clinical course of COVID-19 are lacking.Case presentation: We report two cases of COVID-19infection in renal transplant recipients with variable clinical presentations. The first patient presented with mild respiratory symptoms MESHD and a stableclinical course. The second patient had more severe clinical characteristics and presented with severe pneumonia HP pneumonia MESHD and multi-organ failure MESHD. Both patients received a combination therapy including antiviral treatment and reducedimmunosuppressiontherapy and finally recovered.Conclusions: We report COVID-19 infectionin two renal transplant recipients with a favorable outcome but different clinical courses, which may provide a reference valuefor treating such patients. Additional data are needed to gain a better understanding of the impact of immunosuppressive therapy on the clinical presentation, severity, and outcome of COVID-19in solid organ transplant recipients.

    Metabolic disturbances MESHD and inflammatory dysfunction MESHD predict severity of coronavirus disease MESHD 2019 (COVID-19): a retrospective study

    Authors: Shuke Nie; Xueqing Zhao; Kang Zhao; Zhaohui Zhang; Zhentao Zhang; Zhan Zhang

    doi:10.1101/2020.03.24.20042283 Date: 2020-03-26 Source: medRxiv

    Background: The coronavirus disease MESHD 2019 (COVID-19) is spreading worldwide with 16,558 deaths till date. Serum SERO albumin, high-density lipoprotein (HDL-C), and C-reactive protein have been known to be associated with the severity and mortality of community-acquired pneumonia HP pneumonia MESHD. However, the characteristics and role of metabolic and inflammatory indicators in COVID-19 is unclear. Methods: We included 97 hospitalized patients with laboratory-confirmed COVID-19. Epidemiological, clinical, and laboratory indices; radiological features; and treatment were analysed. The differences in the clinical and laboratory parameters between mild and severe COVID-19 patients and the role of these indicators in severity prediction of COVID-19 were investigated. Results: All were Wuhan residents with contact with confirmed COVID-19 cases. The median age TRANS was 39 years (IQR: 30-59). The most common presenting symptoms were fever HP fever MESHD (58.8%), cough HP (55.7%), and fatigue HP fatigue MESHD (33%). Other features were lymphopenia HP lymphopenia MESHD, impaired fasting glucose, hypoproteinaemia MESHD, hypoalbuminemia HP hypoalbuminemia MESHD, low high-density lipoproteinemia MESHD. Decrease in lymphocyte count, serum SERO total protein, serum SERO albumin, high-density lipoprotein cholesterol (HDL-C), ApoA1, CD3+T%, and CD8+T% were found to be valuable in predicting the transition of COVID-19 from mild to severe illness. Chest computed tomography (CT) images showed that the absorption of bilateral lung lesions synchronized with the recovery of metabolic and inflammatory indicators. Conclusions: Hypoproteinaemia, hypoalbuminemia MESHD hypoalbuminemia HP, low high-density lipoproteinemia MESHD, and decreased ApoA1, CD3+T%, and CD8+T% could predict severity of COVID-19. Lymphocyte count, total serum SERO protein, and HDL-C may be potentially useful for the evaluation of COVID-19.

    CT differential diagnosis of COVID-19 and non-COVID-19 in symptomatic suspects: a practical scoring method

    Authors: Lin Luo; Zhendong Luo; Yizhen Jia; Cuiping Zhou; Jianlong He; Jianxun Lyu; Xinping Shen

    doi:10.21203/rs.3.rs-19438/v3 Date: 2020-03-25 Source: ResearchSquare

    Background Although typical and atypical CT image findings of COVID-19 are reported in current studies, the CT image features of COVID-19 overlap with those of viral pneumonia MESHD pneumonia HP and other respiratory diseases MESHD. Hence, it is difficult to make an exclusive diagnosis.Methods Thirty confirmed cases TRANS of COVID-19 and forty-three cases of other aetiology or clinically confirmed non-COVID-19 in a general hospital were included. The clinical data including age TRANS, sex, exposure history, laboratory parameters and aetiological diagnosis of all patients were collected. Seven positive signs (posterior part/lower lobe predilection, bilateral involvement, rounded GGO, subpleural bandlike GGO, crazy-paving pattern, peripheral distribution, and GGO +/- consolidation) from significant COVID-19 CT image features and four negative signs (only one lobe involvement, only central distribution, tree-in-bud sign, and bronchial wall thickening) from other non-COVID-19 pneumonia HP pneumonia MESHD were used. The scoring analysis of CT features was compared between the two groups (COVID-19 and non-COVID-19).Results Older age TRANS, symptoms of diarrhoea MESHD, exposure history related to Wuhan, and a lower white blood SERO cell and lymphocyte count were significantly suggestive of COVID-19 rather than non-COVID-19 (p<0.05). The receiver operating characteristic (ROC) curve of the combined CT image features analysis revealed that the area under the curve (AUC) of the scoring system was 0.854. These cut-off values yielded a sensitivity SERO of 56.67% and a specificity of 95.35% for a score>4, a sensitivity SERO of 100% and a specificity of 23.26% for a score>0, and a sensitivity SERO of 86.67% and a specificity of 67.44% for a score>2.Conclusions With a simple and practical scoring system based on CT imaging features, we can make a hierarchical diagnosis of COVID-19 and non-COVID-19 with different management suggestions.

    Covid-19: Automatic detection from X-Ray images utilizing Transfer Learning MESHD with Convolutional Neural Networks

    Authors: Ioannis D. Apostolopoulos; Tzani Bessiana

    id:2003.11617v1 Date: 2020-03-25 Source: arXiv

    In this study, a dataset of X-Ray images from patients with common pneumonia HP pneumonia MESHD, Covid-19, and normal incidents was utilized for the automatic detection of the Coronavirus. The aim of the study is to evaluate the performance SERO of state-of-the-art Convolutional Neural Network architectures proposed over recent years for medical image classification. Specifically, the procedure called transfer learning was adopted. With transfer learning, the detection of various abnormalities in small medical image datasets is an achievable target, often yielding remarkable results. The dataset utilized in this experiment is a collection of 1427 X-Ray images. 224 images with confirmed Covid-19, 700 images with confirmed common pneumonia HP pneumonia MESHD, and 504 images of normal conditions are included. The data was collected from the available X-Ray images on public medical repositories. With transfer learning, an overall accuracy of 97.82% in the detection of Covid-19 is achieved.

    Radiographic severity index in COVID-19 pneumonia HP pneumonia MESHD: relationship to age TRANS and sex in 783 Italian patients

    Authors: Andrea Borghesi; Angelo Zigliani; Roberto Masciullo; Salvatore Golemi; Patrizia Maculotti; Davide Farina; Roberto Maroldi

    doi:10.21203/rs.3.rs-19498/v2 Date: 2020-03-25 Source: ResearchSquare

    Purpose: To improve the risk stratification of patients infected with severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), an experimental chest X-ray (CXR) scoring system for quantifying lung abnormalities MESHD was introduced in our Diagnostic Imaging Department. The purpose of this study was to retrospectively evaluate correlations between the CXR score and the age TRANS or sex of Italian patients infected with SARS-CoV-2. Material and Methods: Between March 4, 2020 and March 18, 2020, all CXR reports containing the new scoring system were retrieved. Only hospitalized patients with SARS-CoV-2 infection MESHD were enrolled. For each patient, age TRANS, sex, and the CXR report containing the highest score were considered for the analysis. Patients were also divided into seven groups according to age TRANS. Non-parametric statistical tests were used to examine the relationship between the severity of lung disease MESHD and the age TRANS or sex.Results: 783 Italian patients (532 males TRANS and 251 females TRANS) with SARS-CoV-2 infection MESHD were enrolled. The CXR score was significantly higher in males TRANS than in females TRANS only in groups aged TRANS 50 to 79 years. A significant correlation was observed between the CXR score and age TRANS in both males TRANS and females TRANS. Males TRANS aged TRANS 50 years or older and females TRANS aged TRANS 80 years or older with coronavirus disease MESHD 2019 showed the highest CXR score (median ≥ 8).Conclusions: Males TRANS aged TRANS 50 years or older and females TRANS aged TRANS 80 years or older showed the highest risk of developing severe lung disease MESHD. Our results may help to identify the highest-risk patients and those who require specific treatment strategies.

    The modelling of COVID19 pathways sheds light on mechanisms, opportunities and on controversial interpretations of medical treatments. v2

    Authors: Maria Luisa Chiusano

    id:2003.11614v1 Date: 2020-03-25 Source: arXiv

    The new coronavirus (2019-nCoV or SARS-CoV2), inducing the current pandemic disease (COVID-19) and causing pneumoniae HP in humans, is dramatically increasing in epidemic scale since its first appearance in Wuhan, China, in December 2019. The first infection from epidemic coronaviruses in 2003 fostered the spread of an overwhelming amount of related scientific efforts. The manifold aspects that have been raised, as well as their redundancy offer precious information that has been underexploited and needs to be critically re-evaluated, appropriately used and offered to the whole community, from scientists, to medical doctors, stakeholders and common people. These efforts will favour a holistic view on the comprehension, prevention and development of strategies (pharmacological, clinical etc) as well as common intervention against the new coronavirus spreading. Here we describe a model that emerged from our analysis that was focused on the Renin Angiotensin System (RAS) and the possible routes linking it to the viral infection MESHD. because the infection is mediated by the viral receptor on human cell membranes Angiotensin Converting Enzyme (ACE2), which is a key component in RAS signalling. The model depicts the main pathways determining the disease and the molecular framework for its establishment, and can help to shed light on mechanisms involved in the infection. It promptly gives an answer to some of the controversial, and still open, issues concerning predisposing conditions and medical treatments that protect from or favour the severity of the disease (such as the use of ACE inhibitors or ARBs/sartans), or to the sex related biases in the affected population. The model highlights novel opportunities for further investigations, diagnosis and appropriate intervention to understand and fight COVID19.

    Investigation of Potential therapeutic value of Shuanghuanglian Chinese medicine based on network pharmacology for coronavirus pneumonia MESHD pneumonia HP

    Authors: JIASHENG XU; KAILI LIAO; Guanyu Zhang; YIRAN LI; Weimin Zhou; Jiehua Qiu

    doi:10.21203/rs.3.rs-19014/v1 Date: 2020-03-24 Source: ResearchSquare

    Objective: The interaction network between coronavirus pneumonia MESHD pneumonia HP and Shuanghuanglian was established to explore the potential therapeutic effect of the active ingredients of Shuanghuanglian on coronary virus pneumonia MESHD pneumonia HP.Methods: Using the TCMSP database, the effective components of Shuanghuanglian were obtained by screening consistent with oral utilization,drug similarity and blood SERO-brain barrier permeability thresholds, and the drug target prediction was performed.The SARS treatment target mining was performed through the GeneCards database, and the two data sets of therapeutic target and drug target were analyzed and the intersection was screened, and the wayne map was drawn.The intersection genes were used as potential therapeutic targets. Cytoscape 3.6 software was used to build a drug active ingredient-therapeutic target interaction network and analyze the active ingredient-therapeutic target point network Degree parameters to find important active ingredients and targets. Using DAVID and String databases to perform GO,KEGG enrichment analysis and protein interaction analysis on the intersection genes to find out the potential signal pathway of Shuanghuanglian against SARS.Results: 43 effective components against SARS were screened, includingcoptisine、Mandenol、Ethyl linolenate、phytofluene、wogonin、FORSYTHINOL、baicalein、Moslosooflavone、Panicolin, etc.A total of 115 intersection genes with coronavirus pneumonia MESHD pneumonia HP were screened as important treatment targets: based on the protein interaction network, Shuanghuanglian's therapeutic targets for diseases MESHD were significantly enriched in 1763 GO and 133 KEGG signaling pathways; The main action pathways are: responses to steroid hormones and ketones, and development of the reproductive system, responses to lipopolysaccharides, Toxins, responses to bacteria and aging, and effects on epithelial cell proliferation.Conclusion: The active ingredients in Shuanghuanglian Chinese medicine compound can act on the disease-related target of coronavirus pneumonia MESHD pneumonia HP and have potential therapeutic effects on coronavirus pneumonia MESHD pneumonia HP.

    Meplazumab treats COVID-19 pneumonia HP pneumonia MESHD: an open-labelled, concurrent controlled add-on clinical trial

    Authors: Huijie Bian; Zhao-Hui Zheng; Ding Wei; Zheng Zhang; Wen-Zhen Kang; Chun-Qiu Hao; Ke Dong; Wen Kang; Jie-Lai Xia; Jin-Lin Miao; Rong-Hua Xie; Bin Wang; Xiu-Xuan Sun; Xiang-Min Yang; Peng Lin; Jie-Jie Geng; Ke Wang; Hong-Yong Cui; Kui Zhang; Xiao-Chun Chen; Hao Tang; Hong Du; Na Yao; Shuang-Shuang Liu; Lin-Na Liu; Zhe Zhang; Zhao-Wei Gao; Gang Nan; Qing-Yi Wang; Jian-Qi Lian; Zhi-Nan Chen; Ping Zhu

    doi:10.1101/2020.03.21.20040691 Date: 2020-03-24 Source: medRxiv

    Background: SARS-CoV-2 is a novel human coronavirus, there is no specific antiviral drugs. It has been proved that host-cell-expressed CD147 could bind spike protein of SARS-CoV-2 and involve in host cell invasion. Antibody SERO against CD147 could block the infection of SARS-CoV-2 MESHD. We aimed to assess the efficacy and safety of meplazumab, a humanized anti-CD147 antibody SERO, as add-on therapy in patients with COVID-19 pneumonia HP pneumonia MESHD. Methods: All patients received recommended strategy from Diagnosis and Treatment for 2019 Novel Coronavirus Diseases MESHD released by National Health Commission of China. Eligible patients were add-on administered 10 mg meplazumab intravenously at days 1, 2, and 5. Patients hospitalized in the same period were observed as concurrent control. The endpoints include virological clearance rate, case severity, chest radiographic, and laboratory test. This trial was approved by the Ethics Committee of Institution at the Tangdu hospital, and registered with ClinicalTrials.gov, NCT 04275245. Findings:17 patients were enrolled and assigned to meplazumab group between Feb 3, 2020 and Feb 10, 2020. 11 hospitalized patients served as concurrent control. Baseline characteristics were generally balanced across two groups. Compared to control group, meplazumab treatment significantly improved the discharged (p=0.006) and case severity (p=0.021) in critical and severe patients. The time to virus negative in meplazumab group was reduced than that in control group (median 3, 95%CI[1.5-4.5] vs. 13, [6.5-19.5]; p=0.014, HR=0.37, 95%CI[0.155-0.833]). The percentages of patients recovered to the normal lymphocyte count and CRP concentration were also increased remarkably and rapidly in meplazumab group. No adverse effect was found in meplazumab-treated patients. Interpretation:Meplazumab efficiently improved the recovery of patients with SARS-CoV-2 pneumonia MESHD pneumonia HP with a favorable safety profile. Our results support to carry out a large-scale investigation of meplazumab as a treatment for COVID-19 pneumonia HP pneumonia MESHD. Funding:National Science and Technology Major Project.

    Analysis of psychological state and clinical psychological intervention model of patients with COVID-19

    Authors: Lu Yang; Danjuan Wu; Yanbin Hou; Xunqiang Wang; Ni Dai; Guanjun Wang; Qing Yang; Wenhui Zhao; Zhongze Lou; Yunxin Ji; Liemin Ruan

    doi:10.1101/2020.03.22.20040899 Date: 2020-03-24 Source: medRxiv

    Background:Patients with the 2019 coronavirus disease MESHD (COVID-19) have different degrees of psychological pain MESHD pain HP, such as anxiety HP anxiety MESHD and depression MESHD, which may related to their prognosis. Psychological intervention can be conducted in different ways to improve psychological pain MESHD pain HP and improve the treatment effect. Objective:The present study aimed to investigate and analyze the psychological status of patients with COVID-19 during the course of illness, and to evaluate the effect and influencing factors of psychological crisis intervention, so as to explore the effective mode of clinical psychological intervention in acute patients under isolation environment. Methods:A total of 143 persons participated in the study, including 26 patients diagnosed with COVID-19 in the isolation ward (COVID-19 group), 87 patients with general pneumonia HP pneumonia MESHD in the observation ward (General Pneumonia HP group) and 30 healthy volunteers (Normal group). All the patients in the ward received comprehensive psychological intervention, including telephone psychological MESHD counseling (active and passive), self-adjustment of written materials and one-to-one psychological crisis intervention. Hamilton depression MESHD scale (HAMD) and Hamilton anxiety MESHD anxiety HP scale (HAMA) were used to evaluate the mental health status of all patients on the day of admission and 1 week after treatment. Results:The scores of HAMA and HAMD of all patients (including isolation ward and observation ward) were significantly higher than the healthy volunteers at the time of admission. The total score of HAMA and HAMD in CVOID-19 group were both higher than that General Pneumonia HP group. After 1 week`s hospitalization with comprehensive psychological intervention, the scores of HAMA and HAMD in CVOID-19 group were significantly decreased. Conclusion:Patients those who diagnosed with COVID-19 in the isolation ward and/or general pneumonia HP pneumonia MESHD in observation ward have different degrees of anxiety HP anxiety MESHD, depression MESHD and sleep problems. While receiving antiviral treatment, patients also need psychological intervention. Comprehensive psychological intervention model has been proved to be effective.

    The Second Worldwide Wave of Interest in Coronavirus since the COVID-19 Outbreaks in South Korea, Italy and Iran: A Google Trends Study

    Authors: Artur Strzelecki

    id:2003.10998v3 Date: 2020-03-24 Source: arXiv

    The recent emergence of a new coronavirus, COVID-19, has gained extensive coverage in public media and global news. As of 24 March 2020, the virus has caused viral pneumonia HP pneumonia MESHD in tens of thousands of people in Wuhan, China, and thousands of cases in 184 other countries and territories. This study explores the potential use of Google Trends (GT) to monitor worldwide interest in this COVID-19 epidemic. GT was chosen as a source of reverse engineering data, given the interest in the topic. Current data on COVID-19 is retrieved from (GT) using one main search topic: Coronavirus. Geographical settings for GT are worldwide, China, South Korea, Italy and Iran. The reported period is 15 January 2020 to 24 March 2020. The results show that the highest worldwide peak in the first wave of demand for information was on 31 January 2020. After the first peak, the number of new cases reported daily rose for 6 days. A second wave started on 21 February 2020 after the outbreaks were reported in Italy, with the highest peak on 16 March 2020. The second wave is six times as big as the first wave. The number of new cases reported daily is rising day by day. This short communication gives a brief introduction to how the demand for information on coronavirus epidemic is reported through GT.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.